T cells and B cells in chronic renal failure

Seminars in Nephrology

Volumn 16, Issue 3, 1996, Pages 183-191

  Descamps Latscha, Béatrice ^a   Chatenoud, Lucienne ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS B VACCINE; HLA DR ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; THYMOPENTIN;

ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; B LYMPHOCYTE ACTIVATION; BIOCOMPATIBILITY; CHRONIC KIDNEY FAILURE; CLINICAL PROTOCOL; DIALYSIS MEMBRANE; HELPER CELL; HEPATITIS B VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNE STATUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UREMIA; VACCINATION;

ANIMALS; B-LYMPHOCYTES; HUMANS; KIDNEY FAILURE, CHRONIC; LYMPHOCYTE ACTIVATION; RENAL DIALYSIS; T-LYMPHOCYTES; VACCINATION;

EID: 0029877897     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Dammin GJ, Couch NP, Murray JE: Prolonged survival of skin homografts in uremic patients. Ann NY Acad Sci 64:967-976, 1957
2. Descamps-Latscha B, Herbelin A, Nguyen AT, el al: The immune system in end-stage renal disease. Semin Nephrol 14:253-260, 1994
3. Keane WF, Maddy MF: Host defenses and infectious complications in maintenance hemodialysis patients, in Mayer JF (ed): Replacement of Renal Function by Dialysis. Dordrecht, Kuwer, 1989, pp 865-880
4. Tolkoff-Rubin NE, Rubin RH: Uremia and host defenses editorial; comment. N Engl J Med 322:770-772, 1990
5. Mailloux LU, Bellucci AG, Wilkes BM, el al: Mortality in dialysis patients: Analysis of the causes of death. Am J Kidney Dis 18:326-335, 1991
6. Goldman M, Vanherweghem JL: Bacterial infections in chronic hemodialysis patients: Epidemiologic and pathophysiologic aspects. Adv Nephrol 19:315-327, 1990
7. Haag-Weber M, Horl WH: Uremia and infection: mechanisms of impaired cellular host defense editorial. Nephron 63:125-131, 1993
8. Kessler M, Hoen B, Mayeux D, el al: Bacteremia in patients on chronic hemodialysis. Nephron 64:95-100, 1993
9. Khan IH, Catto GRD: Long-term complications of dialysis - Infection. Kidney Int 43:S143-S148, 1993
10. Mioli VA, La Greca G: A special issue on virus hepatitis and the kidney. Nephron 61:251-376, 1992
11. Jadoul M, Cornu C, van Ypersele de Strihou C, el al: Incidence of risk factors for hepatitis C seroconversion in hemodialysis: A prospective study. Kidney Int 44:1322-1326, 1993
12. Glassock RJ, Cohen AH, Danovitch G, el al: Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med 112:35-49, 1990
13. Marcus R, Favero MS, Banerjee S, el al: Prevalence and incidence of human immunodeficiency virus among patients undergoing long-term hemodialysis. The Cooperative Dialysis Study Group. Am J Med 90:614-619, 1991
14. Tebben JA, Rigsby MO, Selwyn PA, el al: Outcome of HIV infected patients on continuous ambulatory peritoneal dialysis. Kidney Int 44:191-198, 1993
15. Breyer JA, Harbison MA, el al: Isolation of human immunodeficiency virus from peritoneal dialysis. Am J Kidney Dis 21:23-25, 1993
16. Crosnier J, Jungers P, Courouce AM, el al: Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet 1:797-800, 1981
17. Benhamou E, Courouce AM, Jungers P, el al: Hepatitis B vaccine: Randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 21:143-147, 1984
18. Chatenoud L, Herbelin A, Beaurain G, el al: Immune deficiency of the uremic patient. Adv Nephrol 19:259-274, 1990
19. Coplon NS, Diskin CJ, Peterson J, el al: The long term clinical course of systemic lupus erythematosus in end stage renal disease. N Engl J Med 308:186-190, 1983
20. Nolph KD, Husted FC, Sharp GC, el al: Antibodies to nuclear antigens in patients undergoing long-term hemodialysis. Am J Med 60:673-676, 1976
21. Gagnon RF, Shuster J, Kaye M: Auto-immunity in patients with end-stage renal disease maintained on hemodialysis and continuous ambulatory peritoneal dialysis. J Clin Lab Immunol 11:155-158, 1983
22. Hakim RM, Breillatt J, Lazarus JM, el al: Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 311:878-882, 1984
23. Rumpf KW, Seubert S, Seubert A, el al: Association of ethylene-oxide-induced IgE antibodies with symptoms in dialysis patients. Lancet 2:1385-1387, 1985
24. Bommer J, Ritz E: Ethylene oxide (ETO) as a major cause of anaphylactoid reactions in dialysis: A review. Artif Organs 11:111-117, 1987
25. Chatenoud L, Dugas B, Beaurain G, el al: Presence of preactivated T cells in hemodialyzed patients: Their possible role in altered immunity. Proc Natl Acad Sci USA 83:7457-7461, 1986
26. Descamps-Latscha B: The immune system in end stage renal disease. Curr Opin Nephrol Hypertens 2:883-891, 1993
27. Gerez L, Madar L, Shkolnik T, el al: Regulation of interleukin-2 and interferon-gamma gene expression in renal failure. Kidney Int 40:266-272, 1991
28. Newberry WM, Sanford JP: Defective cellular immunity in renal failure: Depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. J Clin Invest 50:1262-1271, 1971
29. Modai D, Berman S, Weissgarten J, el al: Induction of suppressor cell activity in normal peripheral blood mononuclear cells by sera from predialytic uremic patients. Int. Arch. Allergy Appl Immunol 92:268-271, 1990
30. Kamata K, Okubo M, Sada M: Immunosuppressive factors in uraemic sera are composed of both dialysable and non-dialysable components. Clin Exp Immunol 54:277-281, 1983
31. Barsotti G, Bevilacqua G, Morelli E, el al: Toxicity arising from guanidine compounds: Role of methyl guanidine as uremic toxin. Kidney Int 7:S299-S301, 1975
32. Chouaib S, Bertoglio JH: Prostaglandin E as modulators of the immune response. Lymphokine Res 7:237-239, 1988
33. Vanholder R, De Smet R, Hsu C, el al: Uremic toxicity. The middle molecule hypothesis revisited. Semin Nephrol 14:205-218, 1994
34. Massry SG, Smogorzevvski M: Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14:219-231, 1994
35. Ruiz P, Gomez F, Schreiber AD: Impaired function of macrophage Fc receptors in end-stage renal disease. N Engl J Med 322:717-722, 1990
36. Dinarello CA: Cytokines: Agents provocateurs in hemodialysis? Kidney Int 41:683-694, 1992
37. Meuer SC, Hauer M, Kurz P, el al: Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. J Clin Invest 80:743-749, 1987
38. Stachowski J, Pollok M, Burrichter H, el al: Does uremie environment down-regulate T cell activation via TCR/CD3 antigen receptor complex? J Clin Lab Immunol 36:15-21, 1991
39. Sunder-Plassmann G, Heinz G, Wagner L, el al: T-cell selection and T-cell receptor variable beta-chain usage in chronic hemodialysis patients. Clin Nephrol 37:252-259, 1992
40. Klatzmann D, Bensussan A, Gluckman JC, el al: Blood transfusions suppress lymphocyte reactivity in uremic patients. II. Evidence for soluble suppressor factors. Transplantation 36:337-340, 1983
41. Gafter U, Kalechman Y, Sredni B: Induction of a subpopulation of suppressor cells by a single blood transfusion. Kidney Int 41:143-148, 1992
42. Keown PA, Descamps B: Improved renal allograft survival after blood transfusion: A nonspecific, erythrocyte-mediated immunoregulatory process? Lancet 1:20-22, 1979
43. Keown PA, Stiller CR, Descamps-Latscha B: Ferroproteins and the immune response. Lancet 1:44, 1984
44. De Sousa M: Immune functions in iron overload. Clin Exp Immunol 75:1-6, 1989
45. Mattern WD, Hak LJ, Lamanna RW, el al: Malnutrition, altered immune function, and the risk of infection in maintenance hemodialysis patients. Am J Kidney Dis 1:206-218, 1982
46. Collait FE, Dratwa M, Wittek M, el al: Effects of recombinant human erythropoietin on T lymphocyte subsets in hemodialysis patients. ASAIO Trans 36:M219-M223, 1990
47. Grimm PC, Sinai-Trieman L, Sekiya NM, el al: Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 38:12-18, 1990
48. Beaurain G, Naret C, Marcon L, el al: In vivo T cell activation in chronic uremic hemodialyzed patients. Kidney Int 36:636-644, 1989
49. Di Stefano R, Carmellini M, Zucchelli G, el al: Interleukin-2 receptor levels in end-stage renal disease and transplant patients. Transplant Proc 22:1863-1864, 1990
50. Walz G, Kunzendorf U, Josimovic-Alasevic O, el al: Soluble interleukin 2 receptor and tissue polypeptide antigen serum concentrations in end-stage renal failure. Nephron 56:157-161, 1990
51. Nüssberger L, Sturfelt G, Thysell H: Serum levels of the soluble interleukin-2 receptor are dependent on kidney function. Am J Nephrol 12:401-405, 1992
52. Descamps-Latscha B, Herbelin A, Nguyen AT, el al: Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 154:882-892, 1995
53. Caruana RJ, Leffel MS, Lobel SA, el al: Chronic T cell activation in chronic renal failure: A study of hemodialysis, CAPD and pre-dialysis patients. Int J Artif Organs 15:93-98, 1992
54. Zaoui P, Green W, Hakim RM: Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Kidney Int 39:1020-1026, 1991
55. Rabb H, Agosti SJ, Poliard S, el al: Activated and regulatory T lymphocyte populations in chronic hemodialysis patients. Am J Kidney Dis 24:43-45, 1994
56. Goldman M, Druet P: The TH1/TH2 concept and its relevance to renal disorders and transplantation immunity. Nephrol Dial Transplant 10:1282-1284, 1995
57. Stoloff IL, Stout R, Myerson RM, el al: Production of antibody in patients with uremia. N Engl J Med 259:320-323, 1958
58. Borradori L, Born B, Descoeudres C, el al: Serum immunoglobulin levels and natural antibodies to haemophilus influenzae in hemodialysis patients: Evidence for IgG subclass imbalances. Nephron 56:35-39, 1990
59. Beaman M, Michael J, MacLennan IC, el al: T cell independent and T cell dependent antibody response in patients with chronic renal failure. Nephrol Dial Transplant 4:216-221, 1989
60. Kurz P, Köhler H, Meuer S, el al: Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int 29:1209-1214, 1986
61. Paczek L, Schafer RM, Teschner M, el al: Suppression of immunoglobulin and interleukin-6 production from peripheral blood mononuclear cells by dialysis membranes. ASAIO Trans. 36:459-461, 1990
62. Paczek L, Schaefer RM, Heidland A: Improved function of B lymphocytes in dialysis patients treated by recombinant human erythropoietin. Contrib Nephrol 87:36-41, 1980
63. Pfaffl W, Gross HJ, Neumeier D, el al: Lymphocyte subsets and delayed cutaneous hypersensitivity in hemodialysis patients receiving recombinant human erythropoietin. Contrib Nephrol 66:195-204, 1988
64. Sennesael JJ, Van Der Niepen P, Verbeelen DL: Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 40:121-128, 1991
65. Descamps-Latscha B, Herbelin A, Nguyen AT, el al: Soluble CD23 as an effector of immune dysregulation in chronic uremia and dialysis. Kidney Int 43:878-884, 1993
66. Mossalayi MD, Lecron JC, Dalloul AH, el al: Soluble CD23 (FceRII) and interleukin-1 synergistically induce early human thymocyte maturation. J Exp Med 171:959-963, 1990
67. Rytel MW, Dailey MF, Schiffman G, el al: Pneumococcal vaccine immunization of patients with renal impairment. Proc Soc Exp Biol Med 182:468-473, 1986
68. Guérin A, Buisson Y, Nutini MT, el al: Response to vaccination against tetanus in chronic haemodialyzed patients. Nephrol Dial Transplant 7:323-326, 1992
69. Rautenberg P, Teifke I, Schlegelberger T, el al: Influenza subtype-specific IgA, IgM and IgG responses in patients on hemodialysis after influenza vaccination. Infection 16:323-328, 1988
70. Stevens CE, Alter HJ, Taylor PE, el al: Hepatitis B vaccine in patients receiving hemodialysis. N Engl J Med 311:496-501, 1984
71. Kohler H, Arnold W, Renschin G, el al: Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 25:124-128, 1984
72. Benhamou E, Courouce AM, Laplanche A, el al: Long-term results of hepatitis B vaccination in patients on dialysis. N Engl J Med 314:1710-1711, 1986
73. Weissman JY, Tsuchiyose MM, Tong MJ, el al: Lack of response to recombinant hepatitis B vaccine in non responders to the plasma vaccine. JAMA 260:1734-1738, 1988
74. Walz G, Kunzendorf U, Haller H, el al: Factors influencing the response to hepatitis B vaccination of hemodialysis patients. Nephron 51:474-477, 1989
75. Pol S, Legendre C, Mattlinger B, el al: Genetic basis of non-response to hepatitis B vaccine in hemodialyzed patients. J Hepatol 11:385-387, 1990
76. Alper CA. Kruskall MS, Marcus-Bagley D, el al: Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 321:708-712, 1989
77. Caillat-Zucman S, Giminez JJ, Albouze G, el al: HLA genetic heterogeneity of hepatitis B vaccine response in hemodialyzed patients. Kidney Int 43:S157-5160, 1993 (Suppl)
78. Stachowski J, Pollock M, Barth C, el al: Non-responsiveness to hepatitis B vaccination in haemodialysis patients: Association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition. Nephrol Dial Transplant 9:144-152, 1994
79. Meuer SC, Dumann H, Meyer Zum Buschenfelde KH, el al: Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15-18, 1989
80. Quiroga JA, Castillo I, Porres JC, el al: Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 12:661-663, 1990
81. Donati D, Gastaldi L: Controlled trial of thymopentin in hemodialysis patients who failed to respond to hepatitis B vaccination. Nephron 50:133-136, 1988
82. Dumann H, Meuer SC, Renschin G, el al: Influence of thymopentin on antibody response, and monocyte and T cell function in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 55:136-140, 1990
83. Jungers P, Deviller P, Salomon H, el al: Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are nonresponders to hepatitis B vaccine. Lancet 344:856-857, 1994